MCP-1 binding nucleic acids
The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 87 to 115.
1. A method for treating a subject with a kidney disease, comprising administering to said subject an L-nucleic acid that binds a chemokine, wherein said nucleic acid comprises in 5′→3′ direction a first stretch Box B1A, a second stretch Box B2, and a third stretch Box B1B, wherein said first stretch Box B1A comprises a nucleotide sequence selected from the group consisting of ACGCA, CGCA and GCA, said second stretch Box B2 comprises CSUCCCUCACCGGUGCAAGUGAAGCCGYGGCUC (SEQ ID NO:287), and said third stretch Box B1B comprises a nucleotide sequence selected from the group consisting of UGCGU, UGCG and UGC; or a homolog of said L-nucleic acid comprising at least 85% homology.
2. The method of claim 1 , wherein said second stretch Box B2 comprises GUCCCUCACCGGUGCAAGUGAAGCCGUGGCUC (SEQ ID NO:288).
3. The method of claim 1 , wherein
a) said first stretch Box B1A comprises ACGCA, and said third stretch Box B1B comprises UGCGU;
b) said first stretch Box B1A comprises CGCA, and said third stretch Box B1B comprises UGCG; or
c) said first stretch Box B1A comprises GCA, and said third stretch Box B1B comprises UGC or UGCG.
4. The method of claim 1 , wherein said first stretch Box B1A comprises GCA.
5. The method of claim 1 , wherein said third stretch Box B1B comprises UGCG.
6. The method of claim 1 , wherein said chemokine is selected from the group consisting of eotaxin, MCP-1, MCP-2 and MCP-3.
7. The method of claim 1 , wherein said chemokine is human MCP-1.
8. The method of claim 1 , comprising a modification.
9. The method of claim 8 , wherein said modification comprises a hydroxyethyl starch (HES) moiety or a polyethylene glycol (PEG) moiety.
10. The method of claim 8 , wherein said modification comprises a straight or a branched PEG.
11. The method of claim 10 , wherein said straight or branched PEG has a molecular weight from about 20 kD to about 120 kD.
12. The method of claim 9 , wherein said HES moiety has a molecular weight from about 10 kD to about 130 kD.
13. The method of claim 1 , wherein said first stretch Box B1A and said third stretch Box B1B optionally hybridize with each other to form a double-stranded structure.
14. The method of claim 1 , wherein said nucleic acid comprises SEQ ID NO:37, SEQ ID NO:116, SEQ ID NO:117 or SEQ ID NO:278.
15. The method of claim 1 , further comprising administering to said subject a second agent.
16. The method of claim 1 , wherein said disease is autoimmune.
17. The method of claim 1 , wherein said disease is chronic.
18. The method of claim 1 , wherein said disease comprises diabetes.
19. The method of claim 1 , wherein said disease comprises inflammation.
20. The method of claim 1 , wherein said disease comprises albuminuria.